1. Home
  2. HDL vs FTRE Comparison

HDL vs FTRE Comparison

Compare HDL & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HDL

SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

HOLD

Current Price

$13.41

Market Cap

829.7M

ML Signal

HOLD

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$14.98

Market Cap

829.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HDL
FTRE
Founded
2016
1996
Country
Singapore
United States
Employees
14003
N/A
Industry
Restaurants
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
829.7M
829.3M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
HDL
FTRE
Price
$13.41
$14.98
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$14.06
AVG Volume (30 Days)
2.3K
1.5M
Earning Date
05-20-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,723,400,000.00
Revenue This Year
$14.73
N/A
Revenue Next Year
$12.94
$3.09
P/E Ratio
$55.56
N/A
Revenue Growth
N/A
1.00
52 Week Low
$13.31
$3.97
52 Week High
$23.62
$18.67

Technical Indicators

Market Signals
Indicator
HDL
FTRE
Relative Strength Index (RSI) 38.04 74.00
Support Level $13.31 $8.85
Resistance Level $15.40 $18.26
Average True Range (ATR) 0.24 0.88
MACD -0.01 0.52
Stochastic Oscillator 4.59 81.71

Price Performance

Historical Comparison
HDL
FTRE

About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

Super Hi International Holding Ltd is an investment holding company, and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Share on Social Networks: